BioInsights - Vol 6 Issue 4

CELL & GENE THERAPY INSIGHTS

May 2020 Issue

Vol 6 Issue 4

Download PDF

Featuring

Issue Spotlight: Trends and advances in gene therapy delivery and gene editing
Other articles
Webinar

SPOTLIGHT

Trends and advances in gene therapy delivery and gene editing

Expert Insight

Polymer nanoparticles: potential for efficient, biodegradable, and cost-effective delivery of gene therapy to multiple tissues

Polymer nanoparticles: potential for efficient, biodegradable, and cost-effective delivery of gene therapy to multiple tissues

T Fong, S Bodovitz, K Lee
14 May 2020
Read
High dose systemic gene therapy: emerging trends on safety and efficacy

High dose systemic gene therapy: emerging trends on safety and efficacy

H Stedman, R Herzog, G Gao et al.
6 May 2020
Read

Innovator Insight

FectoVIR<sup>®</sup>-AAV: a giant step for AAV large scale manufacturing

FectoVIR®-AAV: a giant step for AAV large scale manufacturing

A Nyamay'antu, M Hellal, M Porte et al.
28 May 2020
Read

Interview

A return to rational capsid design? Predicting the future of AAV vector R&D

A return to rational capsid design? Predicting the future of AAV vector R&D

R Jude Samulski
10 June 2020
Read
Next steps in targeting the CNS with AAV-driven gene therapy

Next steps in targeting the CNS with AAV-driven gene therapy

Bruce Goldsmith
14 May 2020
Read
Gene editing as a key enabler of allogeneic cell therapy

Gene editing as a key enabler of allogeneic cell therapy

Torsten Meissner
4 May 2020
Read
Precise and non-disruptive gene editing based on programmable nickases

Precise and non-disruptive gene editing based on programmable nickases

Manuel Goncalves
23 April 2020
Read

Journal articles

Editorial

Exosome-based therapeutics: ready for prime time

Exosome-based therapeutics: ready for prime time

Konstantin Konstantinov, Jonathan Finn
20 May 2020
Read

Commentary

Exosomes at scale as next-generation cell free medicines: fact and fiction

Exosomes at scale as next-generation cell free medicines: fact and fiction

Ian Dixon
20 May 2020
Read

Interview

An educated approach: AI-enabled neoantigen vaccine R&D

An educated approach: AI-enabled neoantigen vaccine R&D

Roman Yelensky
14 May 2020
Read

Webinars